ENDO GLOBAL VENTURES – Trademark Portfolio
Entity Type: 99
ENDO GLOBAL VENTURES holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 6 filings in this category. The portfolio also extends into Class 16 (Paper Goods) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include XIAFLEX and XIAFLEX COLLAGENASE CLOSTRIDIUM HISTOLYTICUM. The owner is based in HAMILTON.
CANON'S COURT, 22 VICTORIA STREET
HAMILTON HM12 , BM
Showing of trademarks Trademarks
Trademark Classifications
ENDO GLOBAL VENTURES's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does ENDO GLOBAL VENTURES have?
ENDO GLOBAL VENTURES has 8 U.S. trademarks filed with the USPTO. Of these, 3 registered, 5 cancelled.
What trademark classes does ENDO GLOBAL VENTURES file in?
ENDO GLOBAL VENTURES files trademarks across 3 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 16 (Paper Goods), Class 5 (Pharmaceuticals). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.
What are ENDO GLOBAL VENTURES's most well-known trademarks?
ENDO GLOBAL VENTURES's registered trademark portfolio includes well-known marks such as XIAFLEX and XIAFLEX COLLAGENASE CLOSTRIDIUM HISTOLYTICUM. These are among 3 currently registered trademarks in the portfolio.
What is ENDO GLOBAL VENTURES's trademark registration success rate?
ENDO GLOBAL VENTURES has a 38% trademark registration rate, with 3 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.